Investor Newsletter

Issue 06 2023

MicroPort®

MicroPort® Group's Multiple Business Units Participate in the European Cardiovascular Intervention Conference

Recently, the EuroPCR 2023, the European Congress of Cardiology, was held in Paris, France, with over 10,000 experts and scholars in attendance. MicroPort Scientific Corporation (MicroPort®) participated in the event with multiple business units and shared the latest clinical research progress of four products: Bioresorbable Coronary Stent, Drug-Eluting Absorbable Coronary Stent System, Left Atrial Appendage Closure Device, and Transcatheter Aortic Valve System. MicroPort® had the honor of showcasing its integrated solutions in the field of cardiovascular intervention.

During the conference, MicroPort® Coronary, CardioFlow Medtech and Hemovent showcased various products to the attendees, including the Firehawk® Drug-Eluting Stent, Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent system, Firefighter™ PTCA Balloon Catheter, VitaFlow Liberty® Transcatheter Aortic Valve and Retrievable Delivery System, and MOBYBOX™ Extracorporeal Membrane Oxygenation System. These products attracted a large number of attendees, which engaged information exchanges.

As a leading innovative high-end medical device group, MicroPort® will continue to integrate the expertise and experience of top experts from various countries, collaborate with global doctors who are devoted to patients' well-being, and strive to provide better services to patients and offer more high-quality and accessible integrated solutions for patients worldwide.



MicroPort

Endovastec™ participates in the Congresso International de Cirurgia Endovascular

Recently, the 2023 International Congress of Endovascular Surgery (CICE) was held in Brazil, and Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) was invited to participate, set up an exhibition booth, and welcome domestic and international experts to participate in academic discussions.

At this conference, Endovastec™ set up an exclusive booth showcasing a range of innovative products for aortic and peripheral vascular interventions, including the Castor™ Branched Aortic Stent-Graft System (Castor™ Branched Stent System), the Minos™ Abdominal Aortic Stent-Graft and Delivery System (Minos™ Stent-Graft System), the Talos™ Thoracic Aortic Stent-Graft System, and the Reewarm® PTX Drug Coated Balloon PTA Catheter. These products piqued the interest of numerous attendees, encouraging communication and an exchange of information.

South America is one of the regional pioneers of endovascular surgery, and Endovastec™ has had the honor of being invited to participate in the CICE conference for several consecutive years. Since the introduction of Endovastec™'s innovative products at the CICE conference, such as the Castor™ Branched Stent System and the Minos™ Stent-Graft System, these products have gained increasing attention from the South American vascular surgery community. In the future, Endovastec™ will continue to dedicate itself to promoting more high-quality, innovative products for aortic and peripheral vascular interventions to more regions worldwide, benefiting a larger number of patients with circulatory diseases globally.

MicroPort

MicroPort NeuroTech™ has made new progress with multiple products in the international market

Recently, MicroPort NeuroTech™ Co., Ltd., made new progress with multiple products in the international market. Among them, the U-track™ intracranial support catheter system has successfully completed Brazil's first two clinical uses.

U-track™ is the fourth product of NeuroTech™ to enter the Brazilian market. It is also the first access product, providing local neuro-interventional operation patients with high-quality choices.

In addition, MicroPort NeuroTech's NUMEN™ Coil Embolization System (hereinafter referred to as "NUMEN™") and Numen FR® Detachment System (hereinafter referred to as "Numen FR™") have recently obtained registration approval from ANMAT in Argentina. Since their market approval in China in 2020, NUMEN™ and Numen FR™ have successively obtained market approvals in five overseas countries and regions, including CE certification in the European Union, FDA in the United States, MFDS in South Korea, ANVISA in Brazil and MHLW in Japan. They have also achieved clinical implantation in 11 overseas countries across the Asia-Pacific region, North America, and Europe, receiving high praise from local medical teams.

MicroPort

MicroPort EP Exhibiting at the Heart Rhythm Society Annual Meeting

Shanghai MicroPort EP MedTech Co., Ltd. (MicroPort EP) recently participated in the Heart Rhythm Society Annual Scientific Sessions 2023 (HRS 2023) in New Orleans, USA. This marked the first opportunity for MicroPort EP, in the American market, to showcase the latest Columbus™ 3D EP Navigation System V3 and the comprehensive electrophysiology solutions. The exhibition attracted nearly 100 experts and physicians from over 20 countries, including the United States, Italy, France, Switzerland, Spain, and Japan.

As a Chinese company providing a comprehensive solution of 3D cardiac electrophysiology equipment and consumables, MicroPort EP attracted experts and physicians from more than 20 countries, including the United States, Italy, France, Switzerland, Spain, Japan, Turkey, Kazakhstan, Kyrgyzstan, Uzbekistan, Indonesia, Brazil, Dominican Republic, Ecuador, Mexico, and Argentina. Dr. Jose Luis Merino, President of the European Heart Rhythm Association, also visited the booth and exchanged views on MicroPort EP's latest products and technological applications.

To date, MicroPort EP products have been exported to more than 30 countries. In the future, MicroPort EP will continue to build a differentiated product portfolio and expand its global reach, offering comprehensive solutions for diagnosis and therapy of EP interventions to more patients and doctors worldwide.



MicroPort® Sports Medicine's Syntheface® PEEK Interface Screw Obtains US Market Approval

Recently, the Syntheface® PEEK Interface Screw Series, a product developed by Suzhou EndoPhix Medical Technology Co., Ltd., an associated company of Shanghai EndoPhix Medical Technology Co., Ltd. (MicroPort® Sports Medicine), has obtained the 510(K) clearance from the U.S. Food and Drug Administration (FDA).

MicroPort® Sports Medicine will continue to focus on the needs of frontline clinicians, utilizing product innovation as a driving force to promote the development of soft tissue repair technology and provide high-quality and comprehensive service solutions to the field of sports medicine.

MicroPort

Investor Newsletter

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
First Vice President of Board Secretary and Legal Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com